TauC3 Biologics prepares for Series A to advance novel neurodegenerative disease treatment
TauC3 Biologics Ltd, based at Stevenage Bioscience Catalyst, has secured around $2.5 million in new investor commitments, extending the company’s operating runway to Q2 2027 and accelerating the development of its lead antibody programme, TBL-100.